Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CytoNiche
Beijing, Beijing, Chinaen.cytoniche.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CytoNiche's 3D FloTrix platform enabled China's first approved stem cell drug in 2025 and supports commercial stem cell manufacturing; clinical validation includes successful large-scale production and clinical application in at least acute liver failure and additional global trial pipelines[2][5][1].
- Therapeutic areas
- GastroenterologyRare Diseases
- Modalities
- Cell therapyStem cell therapyGene therapyBiologic
- Industry
- Biotech
02
Partnerships
Danaher (collaboration discussions)Partnerships with South Korean, Thai, Indian, and Malaysian companies for APAC expansion
Beyond the preview
Go deeper on CytoNiche.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoNiche.